Paul Wabnitz

BSc, (Hons), MD, PhD, MBA

Clinical Development Consultant

Paul is an expert in clinical trial, drug development, translational medicine, and regulatory approval for first in human trials with industry experience both in Australia and the US and is based in Adelaide Australia. Paul is currently a consultant drug development pharmacologist and toxicologist for clinPHARMA, Executive Medical Director (GPN Vaccines), primary reviewer for the Human Research and Ethics Committee, Bellberry and the Investigative Drug Safety Committee Primary Ethics reviewer. Prior to this Paul was Medical Director at CMAX, Clinical research as well as holding clinical scientist and operational roles at TGR BioSciences, Australia and Esperion Therapeutics, US and Pfizer, US. Paul holds PhD in Organic Chemistry & Cancer Research from the University of Adelaide, is a Doctor of Medicine (Flinders University) and an MBA from the University of Michigan.